We are live on ! Find out more
ARCT icon

Arcturus Therapeutics

31 hedge funds and large institutions have $60.3M invested in Arcturus Therapeutics in 2014 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

83% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 6

29% more funds holding

Funds holding: 2431 (+7)

0% more capital invested

Capital invested by funds: $60.2M → $60.3M (+$30.7K)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

29% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $2.54M

Holders
31
Holders Change
+7
Holders Change %
+29.17%
% of All Funds
0.89%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
10
Increased
11
Reduced
6
Closed
3
Calls
$1.81M
Puts
$2.54M
Net Calls
-$729K
Net Calls Change
-$729K
Name Holding Trade Value Shares
Change
Change in
Stake
U
26
UBS
Switzerland
$45K +$44.7K +370 New
Wells Fargo
27
Wells Fargo
California
$22K -$26.1K -216 -54%
PNC Financial Services Group
28
PNC Financial Services Group
Pennsylvania
$17K
TRCT
29
Tower Research Capital (TRC)
New York
$8K +$7.25K +60 +750%
GSC
30
Ground Swell Capital
South Carolina
$2K +$1.69K +14 New
NFG
31
Next Financial Group
Texas
$1K +$845 +7 New
ACPU
32
Arrowgrass Capital Partners (US)
Delaware
-$1.56M -12,266 Closed
SIM
33
Spark Investment Management
New York
-$487K -3,843 Closed
Citigroup
34
Citigroup
New York
-$10K -81 Closed

ARCT Hedge Fund Activity: Q2 2014 in Review

31 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q2 2014, worth a combined $60.3M — up 0.05% from $60.2M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ARCT positions and 3 closed out — a net gain of 7 holders — while 11 added to existing stakes and 6 trimmed.

The largest buyer was J. Goldman & Co, opening a new position worth an estimated $2.26M. The largest seller was Verition Fund Management, cutting an estimated $3.44M.

  • 31 institutional investors held Arcturus Therapeutics (ARCT) as of Q2 2014, up from 24 in Q1 2014.
  • Funds reported $60.3M of Arcturus Therapeutics stock for Q2 2014, up 0.05% quarter-over-quarter.
  • 10 funds opened new Arcturus Therapeutics positions in Q2 2014 and 3 closed out, a net change of +7 holders.
  • The largest Arcturus Therapeutics buyer in Q2 2014 was J. Goldman & Co, an estimated $2.26M added.
  • The largest Arcturus Therapeutics seller in Q2 2014 was Verition Fund Management, an estimated $3.44M sold.

Based on aggregated 13F filings for Q2 2014.